**Supplementary Fig. 12. Forest plot of adverse events with the SOF-based DAA treatment with and without RBV in patients with decompensated hepatitis C cirrhosis.** Mortality wasincreasedif RBV was added to SOF-based DAA treatment: 89.2% (95% CI: 68.1–99.9) vs. 52.9% (95% CI: 28.0–77.1), *p*=0.0253. SOF, sofosbuvir; RBV, ribavirin; SVR, sustained virologic response; AE, adverse events.

